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ABSTRACT

 ,1 Enxu Zhao,2 Julie Zhu,2 Erin Connolly-Strong,2

Objective SLE is a chronic inflammatory autoimmune
disease characterised by the excessive production of
autoantibodies, immune complexes and proinflammatory
cytokines. Repository corticotropin injection (RCI) is a
naturally sourced complex mixture of adrenocorticotropic
hormone analogues and other pituitary peptides. RCI is
approved by the US Food and Drug Administration for
use during an exacerbation or as maintenance therapy
in select cases of SLE. This paper discusses the design
and baseline characteristics of a multicentre, double-
blind, randomised, placebo-controlled, 24-week clinical
trial evaluating the effect of RCI in reducing disease
activity for patients with persistently active SLE despite
moderate-dose corticosteroid use.
Methods Efficacy will be evaluated using the SLE
Responder Index-4 (SRI-4), SLE Disease Activity
Index-2000 (SLEDAI-2K), British Isles Lupus Assessment
Group-2004 (BILAG-2004) and Physician’s Global
Assessment (PGA). The primary efficacy endpoint
will be the proportion of SRI-4 responders at week
16. Secondary and exploratory endpoints will include
changes in disease activity scores over time, prednisone
dose and biomarkers of inflammation and bone turnover.
The safety and tolerability profile of RCI will also be
evaluated through adverse event profiles, physical
examination, clinical laboratory tests and serum cortisol
levels.
Results Target enrolment for this global study is 270
patients, and as of 15 November 2019, the modified
intent-to-treat population included 169 patients. The
study cohort had 91.7% women, had a mean age of
39.7 years, mean SLEDAI-2K total score of 9.9, mean
BILAG-2004 total score of 18.1, mean PGA of 59.7 and
mean prednisone or equivalent daily dose of 11.1 mg.
A total of 79.3% and 64.5% of patients were receiving
concomitant antimalarial or immunosuppressive therapy,
respectively.
Conclusions Data from this study will provide valuable
insights into the therapeutic role of RCI in refractory SLE,
as well as important information regarding its safety
profile.

Introduction
SLE, a chronic autoimmune disease, affects
multiple organs and has diverse clinical manifestations.1 The goals of SLE treatment are to
reduce disease activity and prevent the accrual
of damage from either the disease itself or the
medications used to treat the disease.2 Corticosteroids, a mainstay of therapy, are a prominent cause of bone loss,3–5 as well as damage
to other organs.6 7 Treatments for persistently active SLE that safely reduce patient
dependence on chronic corticosteroid use
are needed,8 but the complex nature of the
disease has made drug development difficult.
Repository corticotropin injection (RCI;
Acthar Gel) is approved by the US Food
and Drug Administration for use during an
exacerbation or as maintenance therapy in
selected cases of SLE.9 This naturally sourced
complex mixture of purified adrenocorticotropic hormone analogues and other
pituitary peptides achieves both its steroid-
dependent as well as steroid-
independent
anti-
inflammatory effects through melanocortin receptors.10 11 RCI binds to melanocortin receptor 2 (MC2R) to stimulate
steroid hormone secretion from the adrenal
cortex.11 Its additional anti-
inflammatory
effects are produced via direct activation of
MC1R, MC3R, MC4R or MC5R melanocortin
receptors expressed by B and T cells, as well
as in a variety of tissues often affected in
SLE.10–15 These effects include the inhibition
of lymphocyte migration in the skin, lung,
heart, kidney, liver and joints;13–15 reductions
in the expression and secretion of proinflammatory interleukin (IL) 1, IL-6, IL-8,
interferon-γ, tumour necrosis factor-α, IL-2
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and IL-17 and adhesion molecules, including intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin11 13; and increases in regulatory T
(Treg) cells and IL-10.11 Animal studies and evidence
in humans have suggested that the binding of RCI to
MC2R expressed in osteoblasts may also have a protective effect against the bone loss induced by corticosteroids.16 17 This binding stimulates vascular endothelial
growth factor production by osteoblasts to support the
maturation and survival of these cells, as reflected by
reductions in bone resorption markers and increases in
bone formation markers.15 17
Findings from a pilot study suggested that RCI used
with moderate-
dose corticosteroids (prednisone 7.5
to 30 mg/day or equivalent), as well as antimalarials or
immunosuppressants, is safe and well tolerated and may
be effective for patients with persistently active SLE with
rash or arthritis.18 19 Significant benefits of RCI compared
with placebo were observed in secondary analyses of
total hybrid SLE Disease Activity Index (hSLEDAI), total
British Isles Lupus Assessment Group-2004 (BILAG-2004)
and Cutaneous Lupus Erythematosus Disease Area and
Severity Index (CLASI) scores at week 8; benefits were
also significant in post hoc analyses of the SLE Responder
Index-4 (SRI-4) at week 8.18 The hSLEDAI is identical to
the Safety of Estrogens in Lupus National Assessment-
SLEDAI used in clinical trials for belimumab19–22 but uses
the proteinuria definition from the SLE Disease Activity
Index-2000 (SLEDAI-2K). In a separate post hoc analysis
of these pilot study data, treatment with RCI demonstrated sustained improvements in disease activity over
the 52-week study period.23 These results provide a rationale for further clinical investigation of RCI for the treatment of persistently active SLE in larger studies evaluating
validated response measures, such as the SRI-4. Here, we
describe the design and baseline patient characteristics
of this multicentre, randomised, double-blind, placebo-
controlled trial.

Figure 1
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Study objectives
The primary objective of this study is to provide additional data regarding the efficacy and safety of RCI in
patients with SLE requiring moderate-dose corticosteroids. Exploratory objectives include examining pharmacodynamic and steroid-
independent effects of RCI on
lymphocyte recruitment, inflammatory cytokines and
bone turnover.
Methods
Study overview
This prospective, multicentre, randomised, double-
blind, parallel-group, placebo-controlled study will enrol
subjects across approximately 60 study centres worldwide
over a 3-year period. A schematic representation of the
study design is presented in figure 1. Patients with persistently active SLE and moderate to severe rash and/or
arthritis, despite receipt of moderate-
dose corticosteroids and allowed standard of care, will enter a screening
period of up to 28 days before being randomly assigned
to receive RCI 1 mL (80 U) or matching placebo for 24
weeks. Between weeks 16 and 24, patients will be encouraged to taper their corticosteroid dose. A follow-up period
will occur through 28±5 days after the last dose of study
treatment.
Protocol registrations and patient consent
The trial protocol is registered at 
ClinicalTrials.
gov
(NCT02953821). Written informed consent from the
patient is a requirement of enrolment.
Patient population and eligibility
Patients (male or female) who are at least 18 years of
age and have persistently active SLE (≥4 weeks before
screening) despite the use of moderate-dose corticosteroids (prednisone or prednisone equivalent, 7.5 to 30 mg/
day) are eligible for enrolment. Patients are permitted to
enrol if on stable doses of an antimalarial, non-steroidal
anti-
inflammatory drugs (NSAIDs), methotrexate,

Study schematic. QOD, every other day; RCI, repository corticotropin injection.
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Table 1 Key inclusion and exclusion criteria
Inclusion criteria

Exclusion criteria

►► Male or female, ≥18 years of age at screening
►► Females: non-childbearing potential or non-

►► History of sensitivity to ACTH preparations or porcine protein

pregnant, non-lactating and agree to effective
contraception use
►► Males: surgically sterilised or agree to effective
contraception use
►► Diagnosis of SLE according to the American College
of Rheumatology revised criteria
►► Active SLE as demonstrated by a SLEDAI-2K score
≥6 at screening and a clinical SLEDAI-2K score ≥4
(with points for arthritis or rash) at screening and
randomisation
►► Moderate to severe rash or arthritis as demonstrated
by BILAG-2004 score A or B in the mucocutaneous
or musculoskeletal body system at screening and
randomisation
►► On prednisone (or prednisone equivalent) for ≥8
weeks before screening and on a stable dose of 7.5
to 30 mg of prednisone (or prednisone equivalent) for
≥4 weeks before screening
►► Antimalarial/NSAID use: stable dose for ≥4 weeks
before screening and throughout the study
►► Methotrexate/azathioprine/mycophenolate mofetil
use: stable dose for ≥8 weeks before screening and
throughout the study

products

►► Known contraindication(s) to RCI
►► Unwilling to receive or intolerant of subcutaneous injections
►► Severe active lupus nephritis* or required haemodialysis within 3

months before screening or likely to require haemodialysis in the
study
►► Active CNS manifestations of lupus within 3 months before
screening or development of CNS lupus between screening and
the first dose of study drug
►► Received any steroid injection within 4 weeks before screening
►► Received oral prednisone >30 mg/day or equivalent, ciclosporin
or any non-biological investigational drug within 3 months before
screening
►► Received intravenous Ig or plasmapheresis within 4 months before
screening
►► Received cyclophosphamide, abatacept, B-cell-targeted therapy,
B-cell-depleting therapy or any biological investigational agent
within 6 months before screening
►► Known immune compromised status (not related to SLE or SLE
therapies)

*SCr >2.5 mg/dL or protein creatinine ratio >1.5 g/g.
ACTH, adrenocorticotropic hormone; BILAG-2004, British Isles Lupus Assessment Group-2004; CNS, central nervous system; Ig,
immunoglobulin; NSAID, non-steroidal anti-inflammatory drug; RCI, repository corticotropin injection; SCr, serum creatinine; SLEDAI-2K, SLE
Disease Activity Index-2000.

azathioprine or mycophenolate mofetil. Subjects must
have active SLE as demonstrated by a SLEDAI-2K score
≥6 at screening and a clinical SLEDAI-
2K (excluding
laboratory results) score ≥4 at screening and randomisation. SLEDAI-2K points for arthritis and/or rash must be
present at both screening and randomisation. Subjects
must have moderate to severe rash or arthritis as demonstrated by BILAG-2004 scores A or B in the mucocutaneous or musculoskeletal domains at both screening and
randomisation. Patients will be excluded from enrolment
if they have severe renal dysfunction (serum creatinine
>2.5 mg/dL or protein creatinine ratio >1.5 g/g), have
active central nervous system manifestations of lupus
within 3 months before screening or prior to first dose of
study drug, or receive medications not permitted for use
during the study period. These and other key entry and
exclusion criteria are detailed in table 1.
Stratification, randomisation and blinding
Patients determined to be eligible for entry into the study
will be randomly assigned in a 1:1 ratio to receive RCI
1 mL (80 U) or volume-matched placebo (block size, 4).
Randomisation will be stratified by prednisone equivalent
dose (≤20 mg/day vs >20 mg/day) and location (USA vs
ex-USA), with each stratum having a separate computer-
generated randomisation scheme. Both patients and investigators will be blinded to study treatment assignments.

Interventions
The RCI and placebo treatments will be supplied in kits
as 5 mL vials, with the active study drug vials containing
80 U of RCI per millilitre. Before study treatment initiation, patients or their caregivers will be trained on appropriate administration techniques. Patients or caregivers
will complete study diary entries recording all study drug
administrations and will bring the diary and all used
vials to each visit. Each time the study drug is dispensed,
compliance will be encouraged, and study diary entries
will be reviewed.
Treatment is to be administered subcutaneously every
other day for 4 weeks and then twice per week for an
additional 20 weeks. Study staff will supervise the administration of the first dose of treatment in the clinic by the
patient or the patient’s caregiver and will monitor the
patient for allergic or anaphylactic reactions for at least
1 hour post dose. Subsequent doses will be administered
at the patient’s home.
Concomitant medication use
Patients must remain on stable daily doses of topical or
inhaled corticosteroids through week 16 of the study.
Tapering of corticosteroids will be encouraged between
weeks 16 and 24 when clinically appropriate and at the
discretion of the investigator (figure 1). Antimalarials
and NSAIDs will be permitted for patients who have
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Figure 2 Study endpoints. aP values will be derived using Pearson’s χ2 test or Fisher’s exact test, as appropriate. bAnalysis of
covariance models will be used, with treatment group as a factor and baseline value as a covariate; mixed models with repeated
measurement will be performed as necessary. BILAG-2004, British Isles Lupus Assessment Group-2004; CLASI, Cutaneous
Lupus Erythematosus Disease Area and Severity Index; PGA, Physician’s Global Assessment; QOL, quality of life; SFI, Safety of
Estrogens in Lupus Erythematosus National Assessment Flare Index; SLEDAI-2K, SLE Disease Activity Index-2000; SRI-4, SLE
Responder Index-4; WPAI, Work Productivity and Activity Impairment.

been receiving a stable dose for at least 4 weeks before
screening. Methotrexate, azathioprine and mycophenolate mofetil will be permitted for those who have
been receiving a stable dose for at least 8 weeks before
screening. Doses of background antimalarials, NSAIDs
and immunosuppressives must remain constant through
study completion.
Study endpoints
Primary and secondary efficacy outcomes (figure 2) will
be evaluated using the SRI-4 and changes from baseline in
SLEDAI-2K, BILAG-2004, Physician’s Global Assessment
(PGA), CLASI and 28-joint count scores. Total scores for
the BILAG-2004 Index were calculated using the coding
scheme of A=12, B=8, C=1 and D/E=0.24 Exploratory
endpoints and the safety and tolerability profile of RCI
will also be assessed (figure 2).
Statistical methods
The primary analysis set for comparing the efficacy of RCI
and placebo will be the modified intent-to-treat (mITT) population, defined as all randomised patients who receive at
least one dose of study treatment and who provide any
postbaseline efficacy data. Safety and tolerability will be
assessed for the safety population, defined as all patients
who receive one or more doses of study treatment.
4

Enrolment is expected to yield 270 patients screened,
with 169 patients randomised at 60 global study sites. A
sample size of 160 patients (80 per treatment group) was
determined to provide 90% power to demonstrate statistical significance for the primary endpoint, assuming
SRI-4 response rates of 30% in the placebo group and
55% in the RCI group, a significance level of 0.05, and
exclusion of two patients who may not qualify for the
mITT population after randomisation.
For categorical variables including the primary
endpoint, p-values will be derived using Pearson’s χ2
test or Fisher’s exact test, as appropriate. Fisher’s exact
test will be used if the responder or non-
responder
count falls to 5 or lower in either treatment group. For
continuous variables, analysis of covariance models will
be used, with treatment group as a factor and baseline value as a covariate. Mixed models with repeated
measurements will be performed as necessary. All statistical tests will be two-sided, with p-values <0.05 considered statistically significant, and will be performed
using SAS V.9.2 (SAS Institute, Inc., Cary, North Carolina, USA) or higher.
Correlations between clinical scores are determined by
Pearson correlation coefficients. Statistical significance is
determined by t-test.
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Table 2 Baseline demographics and patient characteristics

Characteristic
Age, years, mean (SD)
Female, n (%)

Patients
(mITT
population;
N=169)
39.7 (12.7)
155 (91.7)

Race, n (%)
 Caucasian

63 (37.3)

 African-American

17 (10.1)

 American Indian or Alaska Native

36 (21.3)

 Other

53 (31.4)

Ethnicity, n (%)
 Hispanic or Latino

136 (80.5)

Weight, kg, mean (SD)

73.1 (18.7)

SLEDAI-2K total score, mean (SD)*

9.9 (3.1)

BILAG-2004 total score, mean (SD)†

18.1 (5.3)

Physician’s Global Assessment (0–100 scale),
mean (SD)‡

59.7 (16.2)

Prednisone or equivalent daily dosage, mg,
mean (SD)

11.1 (4.7)

Prednisone or equivalent daily dosage, n (%)
 ≤20 mg/day

161 (95.3)

 >20 mg/day

8 (4.7)

Antimalarials, n (%)
Immunosuppressants, n (%)

134 (79.3)
109 (64.5)

Complement C3, mg/dL, mean (SD)

112.4 (33.5)

Complement C4, mg/dL, mean (SD)
Anti-double stranded DNA antibody, IU/mL,
mean (SD)

19.1 (10.4)
81.1 (192.1)

*SLEDAI-2K was assessed over a 10-day window, and total scores
were the sum of all weighted scores of all 24 manifestations in the
questionnaire.
†The BILAG-2004 Index was assessed over a 4-week period, and
total scores were the sum of scores from all nine organ systems in
the BILAG-2004 questionnaire using the coding scheme of A=12,
B=8, C=1 and D/E=0.
‡n=168.
BILAG-2004, British Isles Lupus Assessment Group-2004;
mITT, modified intent-to-treat; SLEDAI-2K, SLE Disease Activity
Index-2000.

Results
This trial was initiated on 13 October 2016, and 169
patients have been included in the mITT population as
of 15 November 2019. Approximately 92% of the patients
are women. The study cohort had a mean age of 39.7
years, mean SLEDAI-2K total score of 9.9, mean BILAG2004 total score of 18.1, mean PGA of 59.7 and mean
prednisone or equivalent daily dose of 11.1 mg (table 2).
A total of 79.3% have received concomitant antimalarials
and 64.5% immunosuppressive therapy. Baseline levels
of circulating lymphocytes, cytokines and bone turnover
markers are provided in table 3.

To gain a better understanding of the relationship
between our measures of efficacy, we computed correlation
coefficients between them. Statistically significant correlations were found when comparing total SLEDAI-2K total
score with the BILAG-2004 total score (r=0.4, p<0.0001)
and CLASI total activity score (r=0.4, p<0.0001); PGA with
tender and swollen joint counts (r=0.4, p<0.0001), CLASI
total activity score (r=0.2, p=0.0032) and the BILAG-2004
score (r=0.2, p=0.0108); and the BILAG-2004 total score
with the CLASI total activity score (r=0.5, p<0.0001) and
tender and swollen joint counts (r=0.2, p=0.0026).
Discussion
In this large, randomised, double-
blind, placebo-
controlled study of RCI for the treatment of persistently
active SLE, demographics and baseline characteristics
are consistent with those from other studies of active SLE
populations.18 25 Activity of SLE in this cohort is indicated
by a mean SLEDAI-2K total score of 9.9, mean BILAG2004 total score of 18.1 and mean PGA of 59.7. Most of
the currently enroled patients (95.3%) are on a prednisone (or equivalent) dosage of ≤20 mg/day.
This trial will use the validated composite response
measure SRI-4 as the primary endpoint and will also evaluate pharmacodynamics (cell surface markers for lymphocytes, cytokines and serum bone turnover markers).
Biological activity of RCI in the treatment of SLE
may extend beyond stimulation of adrenal corticosteroid production. MC1R, MC3R, MC4R and MC5R are
expressed on multiple leucocyte subpopulations (eg, T
and B cells, macrophages), as well as within target organs
(eg, skin, kidney, central nervous system) relevant to
SLE.13 In a murine model, RCI has been shown to reduce
B-cell differentiation and development, and to decrease
circulating autoantibodies, proteinuria, renal lymphocyte
infiltration and glomerular immune complex deposition.11 Finally, in an in vitro study using peripheral blood
B cells isolated from healthy human subjects, RCI dose
dependently inhibited IL-4/CD40 ligand-induced B-cell
proliferation and IgG production without enhancing cell
death.26
These data suggest that RCI not only directly affects
human B-
cell function but also provides supportive
evidence for steroid-
independent effects of RCI when
used as a treatment for SLE. Therefore, it is hypothesised
that, in addition to clinical improvements, the steroid-
independent effects of RCI will result in the reduction of
inflammatory cytokines and minimal bone turnover rates.
Potential limitations of this study are the lack of stratification by factors beyond location and prednisone (or
equivalent) dose. Factors such as disease severity and/or
background therapies could affect the response to RCI
therapy.
Conclusions
This randomised, double-
blind, placebo-
controlled
study was designed on the basis of signals of efficacy and

Askanase AD, et al. Lupus Science & Medicine 2020;7:e000383. doi:10.1136/lupus-2020-000383

5

Lupus Science & Medicine
Table 3 Baseline circulating lymphocyte, cytokine and bone turnover markers (mITT population)
Biomarkers

n

Cells/µL

Ratio (%)

Circulating lymphocyte profile: CD19 B cells, mean (SD)
 Naive B cells (IgD+CD27-)

159

127.7 (122.4)

55.2 (21.0)

 Unswitched memory cells (IgD+CD27+)

159

13.5 (12.0)

9.8 (9.2)

159

39.7 (37.2)

22.6 (13.1)

 Double-negative memory cells (IgD CD27 )

159

21.2 (24.2)

11.8 (9.6)

 Atypical activated memory cells (IgD-CD27-CD95+)

159

6.4 (10.2)

32.7 (18.2)

159

699.9 (415.1)

46.2 (10.7)

159

436.1 (252.5)

30.4 (10.1)

 Double-negative T cells (CD4 CD8 )

159

34.0 (44.7)

2.5 (3.8)

 Double-positive T cells (CD4+CD8+)

159

12.6 (13.6)

0.9 (0.7)

136

63.0 (185.8)

14.2 (11.2)

 Effector Treg cells (CD25 -FoxP3 - CD45RA )
 Non-suppressive cells (CD25+ -FoxP3low- CD45RA-)

136
136

58.6 (106.7)
253.5 (501.4)

21.8 (13.5)
61.0 (13.7)

Cytokines and bone turnover markers

n

pg/mL, ng/mL, µg/L

Cytokines, mean (SD)
 IL-6

151

8.0 (16.1) pg/mL

 IL-10

135

1.0 (1.0) pg/mL

 IL-17

151

0.2 (0.3) pg/mL

 Type I IFN-α

157

13.7 (6.3) pg/mL

 BAFF

149

1401.2 (937.0) pg/mL

 sVCAM-1

157

1004.2 (420.9) ng/mL

160
160

45.8 (24.6) µg/L
0.4 (0.2) µg/L

+

-

+

 Switched memory cells (IgD CD27 )
-

-

+

Circulating lymphocyte profile: CD3 total T cells, mean (SD)
 Helper T cells (CD4+CD8-)
-

+

 Cytotoxic T cells (CD4 CD8 )
-

-

+

Circulating lymphocyte profile: CD4 Treg cells, mean (SD)
 Naive Treg cells (CD25+ -FoxP3low- CD45RA+)
+

high

-

Bone turnover markers, mean (SD)
 PINP
 CTX-I

BAFF, B-cell-activating factor; CTX-I, C-terminal crosslinking telopeptide of type I collagen; IFN, interferon; IL, interleukin; mITT, modified
intent-to-treat; PINP, N-terminal propeptide of type I collagen; sVCAM, soluble vascular cell adhesion molecule; Treg, regulatory T.

safety observed in a previous pilot study. The findings are
intended to support RCI as an effective therapeutic option
for the treatment of patients with persistently active SLE
receiving moderate-
dose corticosteroids. Correlations
between clinical outcomes and pharmacodynamic measures, including circulating lymphocyte profiles, cytokines
and bone turnover markers may help elucidate the mechanisms of RCI.
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